CADTH | Evidence Driven
CADTH | Evidence Driven

exagamglogene autotemcel

Details

Generic Name:
exagamglogene autotemcel
Project Status:
Pending
Therapeutic Area:
Transfusion-dependent β-thalassemia
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SG0831-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​Exagamglogene autotemcel is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Exagamglogene autotemcel is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years and older.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : March 19, 2024